Engineering improved technology for nanoparticle-based adjuvant manufacture

在接下来的十年里，纳米技术将重新定义用于动物和人类健康的疫苗。纳米颗粒佐剂将增强使用最小抗原（如重组蛋白和合成肽）的工程疫苗。本项目旨在通过优化菊粉纳米颗粒的工程和制造方面，从根本上了解菊粉纳米颗粒的理化性质与功效之间的关系，开发一种制备和控制菊粉纳米颗粒性能的平台技术。该项目的完成旨在生产以新型制造技术为基础的强效纳米颗粒佐剂，最终促进为动物和人类开发更有效和更具保护性的疫苗。

Over the next decade nanotechnology will redefine vaccines for animal and human health. Nanoparticle adjuvants will boost engineered vaccines that use minimal antigens such as recombinant proteins and synthetic peptides. This project aims to develop a platform technology for making and controlling the properties of inulin nanoparticles by optimising the engineering and manufacturing aspects of inulin nanoparticles to fundamentally understand the relationship between physical-chemical properties and efficacy. Completion of this project aims to produce potent nanoparticle-based adjuvants underpinned by novel manufacturing technology, to ultimately facilitate the development of more effective and protective vaccines for animals and humans.